DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Rebeccamycin is an investigational drug.
There have been 12 clinical trials for Rebeccamycin. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 1999.
The most common disease conditions in clinical trials are Lymphoma, Neuroblastoma, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Case Comprehensive Cancer Center, and Barbara Ann Karmanos Cancer Institute.
Recent Clinical Trials for Rebeccamycin
|Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors||National Cancer Institute (NCI)||Phase 1|
|Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia||National Cancer Institute (NCI)||Phase 1|
|Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy||National Cancer Institute (NCI)||Phase 2|